标题
Potential of antibody–drug conjugates (ADCs) for cancer therapy
作者
关键词
-
出版物
Cancer Cell International
Volume 22, Issue 1, Pages -
出版商
Springer Science and Business Media LLC
发表日期
2022-08-13
DOI
10.1186/s12935-022-02679-8
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Unlocking the potential of antibody–drug conjugates for cancer therapy
- (2021) Joshua Z. Drago et al. Nature Reviews Clinical Oncology
- Linker Design Impacts Antibody-Drug Conjugate Pharmacokinetics and Efficacy via Modulating the Stability and Payload Release Efficiency
- (2021) Dian Su et al. Frontiers in Pharmacology
- Protease‐activated prodrugs: strategies, challenges, and future directions
- (2020) Marcin Poreba FEBS Journal
- Antitumor Activity and Safety of Trastuzumab Deruxtecan in Patients With HER2-Low–Expressing Advanced Breast Cancer: Results From a Phase Ib Study
- (2020) Shanu Modi et al. JOURNAL OF CLINICAL ONCOLOGY
- U1 snRNP regulates cancer cell migration and invasion in vitro
- (2020) Jung-Min Oh et al. Nature Communications
- Targeting apoptosis in cancer therapy
- (2020) Benedito A. Carneiro et al. Nature Reviews Clinical Oncology
- Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer
- (2020) Kohei Shitara et al. NEW ENGLAND JOURNAL OF MEDICINE
- HER2-Mediated Internalization of Cytotoxic Agents in ERBB2 Amplified or Mutant Lung Cancers
- (2020) Bob T. Li et al. Cancer Discovery
- Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer
- (2019) Aditya Bardia et al. NEW ENGLAND JOURNAL OF MEDICINE
- Antibody-Drug Conjugate-Based Therapeutics: State of the Science
- (2019) Michael J Birrer et al. JNCI-Journal of the National Cancer Institute
- Engineering a HER2-specific antibody–drug conjugate to increase lysosomal delivery and therapeutic efficacy
- (2019) Jeffrey C. Kang et al. NATURE BIOTECHNOLOGY
- Pivotal Trial of Enfortumab Vedotin in Urothelial Carcinoma After Platinum and Anti-Programmed Death 1/Programmed Death Ligand 1 Therapy
- (2019) Jonathan E. Rosenberg et al. JOURNAL OF CLINICAL ONCOLOGY
- A view on drug resistance in cancer
- (2019) Neil Vasan et al. NATURE
- Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer
- (2019) Shanu Modi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Modulating Antibody–Drug Conjugate Payload Metabolism by Conjugation Site and Linker Modification
- (2018) Dian Su et al. BIOCONJUGATE CHEMISTRY
- Ado-Trastuzumab Emtansine for Patients With HER2-Mutant Lung Cancers: Results From a Phase II Basket Trial
- (2018) Bob T. Li et al. JOURNAL OF CLINICAL ONCOLOGY
- Fate of Antibody-Drug Conjugates in Cancer Cells
- (2018) Cécile Chalouni et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Glutamic acid–valine–citrulline linkers ensure stability and efficacy of antibody–drug conjugates in mice
- (2018) Yasuaki Anami et al. Nature Communications
- Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer
- (2018) Gunter von Minckwitz et al. NEW ENGLAND JOURNAL OF MEDICINE
- Small molecule-drug conjugates: A novel strategy for cancer-targeted treatment
- (2018) Chunlin Zhuang et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Targeted radionuclide therapy in combined-modality regimens
- (2017) Martin R Gill et al. LANCET ONCOLOGY
- Next generation antibody drugs: pursuit of the 'high-hanging fruit'
- (2017) Paul J. Carter et al. NATURE REVIEWS DRUG DISCOVERY
- Strategies and challenges for the next generation of antibody–drug conjugates
- (2017) Alain Beck et al. NATURE REVIEWS DRUG DISCOVERY
- Understanding CD30 biology and therapeutic targeting: a historical perspective providing insight into future directions
- (2017) C A van der Weyden et al. Blood Cancer Journal
- Intracellular trafficking of new anticancer therapeutics: antibody–drug conjugates
- (2017) Muhammad Kalim et al. Drug Design Development and Therapy
- Promiximab-duocarmycin, a new CD56 antibody-drug conjugates, is highly efficacious in small cell lung cancer xenograft models
- (2017) Lin Yu et al. Oncotarget
- Antibody structure and engineering considerations for the design and function of Antibody Drug Conjugates (ADCs)
- (2017) Ricarda M. Hoffmann et al. OncoImmunology
- Capturing Biological Activity in Natural Product Fragments by Chemical Synthesis
- (2016) Erika A. Crane et al. ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
- Antibody drug conjugates: lessons from 20 years of clinical experience
- (2016) A. W. Tolcher ANNALS OF ONCOLOGY
- Combining antibody–drug conjugates and immune-mediated cancer therapy: What to expect?
- (2016) Hans-Peter Gerber et al. BIOCHEMICAL PHARMACOLOGY
- Antibody-drug conjugates—an emerging class of cancer treatment
- (2016) Nikolaos Diamantis et al. BRITISH JOURNAL OF CANCER
- A Biparatopic HER2-Targeting Antibody-Drug Conjugate Induces Tumor Regression in Primary Models Refractory to or Ineligible for HER2-Targeted Therapy
- (2016) John Y. Li et al. CANCER CELL
- Intracellular Released Payload Influences Potency and Bystander-Killing Effects of Antibody-Drug Conjugates in Preclinical Models
- (2016) F. Li et al. CANCER RESEARCH
- Enfortumab Vedotin Antibody-Drug Conjugate Targeting Nectin-4 Is a Highly Potent Therapeutic Agent in Multiple Preclinical Cancer Models
- (2016) P. M. Challita-Eid et al. CANCER RESEARCH
- Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity
- (2016) Yusuke Ogitani et al. CANCER SCIENCE
- Editorial overview: Special section: New concepts in antibody therapeutics: What's in store for antibody therapy?
- (2016) Janine Schuurman et al. CURRENT OPINION IN IMMUNOLOGY
- Linkers Having a Crucial Role in Antibody–Drug Conjugates
- (2016) Jun Lu et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Quantitative characterization of in vitro bystander effect of antibody-drug conjugates
- (2016) Aman P. Singh et al. JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS
- Discovery of Pyrophosphate Diesters as Tunable, Soluble, and Bioorthogonal Linkers for Site-Specific Antibody–Drug Conjugates
- (2016) Jeffrey C. Kern et al. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
- Biodistribution and Targeting of Anti-5T4 Antibody-Drug Conjugate Using Fluorescence Molecular Tomography
- (2016) A. Giddabasappa et al. MOLECULAR CANCER THERAPEUTICS
- Expanding the Reach of Antibody–Drug Conjugates
- (2016) Ravi V. J. Chari ACS Medicinal Chemistry Letters
- Antibody-drug conjugates: recent advances in conjugation and linker chemistries
- (2016) Kyoji Tsuchikama et al. Protein & Cell
- Structural Basis of Microtubule Destabilization by Potent Auristatin Anti-Mitotics
- (2016) Andrew B. Waight et al. PLoS One
- Advances in Antibody Design
- (2015) Kathryn E. Tiller et al. Annual Review of Biomedical Engineering
- Strategies and Advancement in Antibody-Drug Conjugate Optimization for Targeted Cancer Therapeutics
- (2015) Eunhee G. Kim et al. Biomolecules & Therapeutics
- Antibody-drug conjugates as novel anti-cancer chemotherapeutics
- (2015) C. Peters et al. BIOSCIENCE REPORTS
- Emerging formats for next-generation antibody drug conjugates
- (2015) Mahendra P Deonarain et al. Expert Opinion on Drug Discovery
- Antibody–Drug Conjugates and Small Molecule–Drug Conjugates: Opportunities and Challenges for the Development of Selective Anticancer Cytotoxic Agents
- (2015) Giulio Casi et al. JOURNAL OF MEDICINAL CHEMISTRY
- Anti-CD22 and anti-CD79B antibody drug conjugates are active in different molecular diffuse large B-cell lymphoma subtypes
- (2015) M Pfeifer et al. LEUKEMIA
- AMG 595, an Anti-EGFRvIII Antibody-Drug Conjugate, Induces Potent Antitumor Activity against EGFRvIII-Expressing Glioblastoma
- (2015) K. J. Hamblett et al. MOLECULAR CANCER THERAPEUTICS
- Tumor Cells Chronically Treated with a Trastuzumab-Maytansinoid Antibody-Drug Conjugate Develop Varied Resistance Mechanisms but Respond to Alternate Treatments
- (2015) F. Loganzo et al. MOLECULAR CANCER THERAPEUTICS
- Mechanisms of action of therapeutic antibodies for cancer
- (2015) J.M. Redman et al. MOLECULAR IMMUNOLOGY
- Recent Advances in the Development of New Auristatins: Structural Modifications and Application in Antibody Drug Conjugates
- (2015) Andreas Maderna et al. MOLECULAR PHARMACEUTICS
- Design, Synthesis, and Evaluation of Linker-Duocarmycin Payloads: Toward Selection of HER2-Targeting Antibody–Drug Conjugate SYD985
- (2015) Ronald C. Elgersma et al. MOLECULAR PHARMACEUTICS
- Current ADC Linker Chemistry
- (2015) Nareshkumar Jain et al. PHARMACEUTICAL RESEARCH
- FDA Approval: Ado-Trastuzumab Emtansine for the Treatment of Patients with HER2-Positive Metastatic Breast Cancer
- (2014) L. Amiri-Kordestani et al. CLINICAL CANCER RESEARCH
- IgG Subclasses and Allotypes: From Structure to Effector Functions
- (2014) Gestur Vidarsson et al. Frontiers in Immunology
- SGN-CD33A: a novel CD33-targeting antibody-drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AML
- (2013) M. S. Kung Sutherland et al. BLOOD
- Antibody–drug conjugates: current status and future directions
- (2013) Heidi L. Perez et al. DRUG DISCOVERY TODAY
- Implications of receptor-mediated endocytosis and intracellular trafficking dynamics in the development of antibody drug conjugates
- (2013) Michael Ritchie et al. mAbs
- Site-specific antibody drug conjugates for cancer therapy
- (2013) Siler Panowski et al. mAbs
- Milatuzumab-SN-38 Conjugates for the Treatment of CD74+ Cancers
- (2013) S. V. Govindan et al. MOLECULAR CANCER THERAPEUTICS
- Maturing antibody–drug conjugate pipeline hits 30
- (2013) Asher Mullard NATURE REVIEWS DRUG DISCOVERY
- AKT Signaling as a Novel Factor Associated with In Vitro Resistance of Human AML to Gemtuzumab Ozogamicin
- (2013) David B. Rosen et al. PLoS One
- Characterization of the drug-to-antibody ratio distribution for antibody–drug conjugates in plasma/serum
- (2013) Keyang Xu et al. Bioanalysis
- Antibody-Drug Conjugates in Cancer Therapy
- (2012) Eric L. Sievers et al. Annual Review of Medicine
- Reversal of ATP-binding cassette drug transporter activity to modulate chemoresistance: why has it failed to provide clinical benefit?
- (2012) Man Yu et al. CANCER AND METASTASIS REVIEWS
- Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's Lymphoma
- (2012) Anas Younes et al. JOURNAL OF CLINICAL ONCOLOGY
- Doxorubicin: an update on anticancer molecular action, toxicity and novel drug delivery systems
- (2012) Oktay Tacar et al. JOURNAL OF PHARMACY AND PHARMACOLOGY
- A mechanistic compartmental model for total antibody uptake in tumors
- (2012) Greg M. Thurber et al. JOURNAL OF THEORETICAL BIOLOGY
- Importance of inducible multidrug resistance 1 expression in HL-60 cells resistant to gemtuzumab ozogamicin
- (2012) Taichi Matsumoto et al. LEUKEMIA & LYMPHOMA
- Intratumoral heterogeneity of HER2 gene amplification in breast cancer: its clinicopathological significance
- (2012) Hyesil Seol et al. MODERN PATHOLOGY
- The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma
- (2012) Peter D Senter et al. NATURE BIOTECHNOLOGY
- Brentuximab vedotin
- (2012) Anas Younes et al. NATURE REVIEWS DRUG DISCOVERY
- Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer
- (2012) Sunil Verma et al. NEW ENGLAND JOURNAL OF MEDICINE
- Antibody Conjugate Therapeutics: Challenges and Potential
- (2011) B. A. Teicher et al. CLINICAL CANCER RESEARCH
- Antibody-Maytansinoid Conjugates Designed to Bypass Multidrug Resistance
- (2010) Y. V. Kovtun et al. CANCER RESEARCH
- Antibody–drug conjugates: targeted drug delivery for cancer
- (2010) Stephen C Alley et al. CURRENT OPINION IN CHEMICAL BIOLOGY
- Assessment of EGFR Mutation Status in Lung Adenocarcinoma by Immunohistochemistry Using Antibodies Specific to the Two Major Forms of Mutant EGFR
- (2010) Marie Brevet et al. JOURNAL OF MOLECULAR DIAGNOSTICS
- Maytansine and Cellular Metabolites of Antibody-Maytansinoid Conjugates Strongly Suppress Microtubule Dynamics by Binding to Microtubules
- (2010) M. Lopus et al. MOLECULAR CANCER THERAPEUTICS
- Maytansinoid-Antibody Conjugates Induce Mitotic Arrest by Suppressing Microtubule Dynamic Instability
- (2010) E. Oroudjev et al. MOLECULAR CANCER THERAPEUTICS
- Biodistribution Mechanisms of Therapeutic Monoclonal Antibodies in Health and Disease
- (2009) Mohammad Tabrizi et al. AAPS Journal
- Strongly Enhanced Antitumor Activity of Trastuzumab and Pertuzumab Combination Treatment on HER2-Positive Human Xenograft Tumor Models
- (2009) W. Scheuer et al. CANCER RESEARCH
- Deficient activation of Bak and Bax confers resistance to gemtuzumab ozogamicin-induced apoptotic cell death in AML
- (2009) Petra Haag et al. EXPERIMENTAL HEMATOLOGY
- Antibody-Drug Conjugates for Cancer Therapy
- (2008) Paul J. Carter et al. CANCER JOURNAL
- Targeted Cancer Therapy: Conferring Specificity to Cytotoxic Drugs
- (2007) Ravi V. J. Chari ACCOUNTS OF CHEMICAL RESEARCH
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started